ClinicalTrials.gg
DrugRead study by study

Olaparib clinical trials

Also written Lynparza, AZD2281 and KU-0059436.

studies test it
323
open now
61
in phase 3
38
first study started
2005
ClinicalTrials.gov finds 505 studies for olaparib. How that becomes 323 here

Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives olaparib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 505Found by its intervention search · See all 505 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 446 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −4
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. −1New since the last reading, not read yet
  4. 500Give olaparib to participants
  5. −40Observe patients on it, or give it outside a trial
  6. −5Use it as a tool: an imaging tracer or a test of drug response
  7. −2Compare another treatment with it
  8. −130Give it beside what is tested
  9. 323Test it: the count on this site

Get an email when these change. Save the olaparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Dec 2014 · LYNPARZA · NDA 206162 (FDA, Drugs@FDA)
European Union
16 Dec 2014 · Lynparza · EMEA/H/C/003726 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Olaparib
243
PARP Inhibitor AZD2281
16
KU-0059436 (AZD2281)(PARP inhibitor)
7
Olaparib tablet
5
Olaparib 300mg tablets
3

Brand

Lynparza
112

Development codes

AZD2281
61
KU-0059436
32
MK-7339
11
BR2022
1
AZ2281
1

Studies by the year they started

321 studies that test it; most in 2019 (37); 1 more planned to start later

Studies that test olaparib, by start year
YearStudies
20051
20077
200811
20092
20105
20114
20127
201312
201413
201510
201622
201720
201834
201937
202029
202130
202229
202319
202416
20257
20266

Who runs them

Industry 84 · Other 239

AstraZeneca (64) · National Cancer Institute (NCI) (30) · Merck Sharp & Dohme LLC (12) · M.D. Anderson Cancer Center (9) · Memorial Sloan Kettering Cancer Center (8) · The Netherlands Cancer Institute (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · University of Washington (4)

Often tested with

Tested in the same studies.

Pembrolizumab (38) · Durvalumab (37) · Palbociclib (13) · Temozolomide (12) · Cediranib (11) · Pertuzumab (10) · Atezolizumab (9) · Carboplatin (9)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Olaparib is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with olaparib beside them; studies of each.

Reaching primary completion within a year · 32, 3 in phase 3

Studies that test olaparib, phase 3 first.

Studies

Open first, then newest update. How each study uses olaparib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 323

See all 323 studies that test olaparib →

Behind its US label · 8 — the studies the FDA label of LYNPARZA describes

From the Clinical Studies section of LYNPARZA (2025-07), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 100 — no other medicine in its arm

Showing 20 of 100. See all 100 →

Tested with established drugs · 48 — they are given beside it

Showing 20 of 48. See all 48 →

Tested in a combination · 175 — another drug in the study is under test too

Showing 20 of 175. See all 175 →

Beside an established treatment under test · 21 — an approved drug, surgery or radiation is what the study tests

Tested with olaparib: Surgery or a procedure 10 · Radiation 3 · pembrolizumab 2 · durvalumab 2 · atezolizumab 1 · copanlisib hydrochloride 1 · sacituzumab govitecan 1 · abemaciclib 1

Showing 20 of 21. See all 21 →

Beside a new treatment under test · 103 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with olaparib: cediranib 15 · ceralasertib 14 · tremelimumab 5 · capivasertib 5 · durvalumab 4 · adavosertib 4 · IT-101 3 · Iparomlimab/Tuvonralimab 3

Showing 20 of 103. See all 103 →

Beside supportive care · 2 — a supportive treatment or test is studied
One option of several · 4 — a test or a strategy chooses among drugs
As the comparator · 2 — what is tested is compared with olaparib
Observed · 40 — patients on it are followed, or it is given outside a trial

Showing 20 of 40. See all 40 →

As a tool · 5 — an imaging tracer or a test of drug response

Codes

What other systems call olaparib · ClinicalTrials.gg INT005326

  • MeSH (NLM) C531550olaparibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) WOH1JD9AR8OLAPARIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1597582Confirmed FDA, Wikidata
  • Wikidata Q7083106olaparibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C71721OlaparibOne source FDA
  • DrugBank DB09074One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion